Myovant Sciences GmbH
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$6.7M
Doctors Paid
68
Transactions
1,240
2022 Total
$3.8M
Payment Breakdown by Category
Research$6.7M (99.8%)
Travel$5,444 (0.1%)
Food & Beverage$4,019 (0.1%)
Consulting$3,589 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.7M | 1,166 | 99.8% |
| Travel and Lodging | $5,444 | 8 | 0.1% |
| Food and Beverage | $4,019 | 63 | 0.1% |
| Consulting Fee | $3,589 | 1 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,385 | 2 | 0.0% |
Payments by Type
Research
$6.7M
1,166 transactions
General
$15,437
74 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A TWO-PART, OPEN-LABEL, FIXED-SEQUENCE, TWO-PERIOD CROSSOVER STUDY TO ASSESS THE EFFECTS OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF RELUGOLIX, ESTRADIOL AND NORETHINDRONE AFTER ADMINISTRATION OF THE RELUGOLIX/ESTRADIOL/NORETHINDRONE ACETATE FIXED-DOSE COMBINATION TABLET IN HEALTHY POSTMENOPAUSAL WOMEN OR OF RELUGOLIX AFTER ADMINISTRATION OF A SINGLE 120-MG DOSE IN HEALTHY ADULT MEN | $2.2M | 0 | 18 |
| A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy | $1.5M | 2 | 447 |
| Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis | $1.3M | 2 | 571 |
| AN OPEN-LABEL, FIXED (SINGLE)-SEQUENCE CROSSOVER STUDY TO ASSESS THE SUFFICIENCY OF DOSE SEPARATION TO MITIGATE ABSORPTION MEDIATED INCREASES IN EXPOSURE TO RELUGOLIX RESULTING FROM INHIBITION OF INTESTINAL P-GP BY AZITHROMYCIN IN HEALTHY ADULT MEN | $797,660 | 0 | 17 |
| AN OPEN-LABEL, FIXED SINGLE -SEQUENCE CROSSOVER STUDY TO ASSESS THE SUFFICIENCY OF DOSE SEPARATION TO MITIGATE ABSORPTION MEDIATED INCREASES IN EXPOSURE TO RELUGOLIX RESULTING FROM INHIBITION OF INTESTINAL P-GP BY AZITHROMYCIN IN HEALTHY ADULT MEN | $446,389 | 0 | 15 |
| A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN HEALTHY WOMEN 18 TO 35 YEARS OF AGE WHO ARE AT RISK FOR PREGNANCY | $410,840 | 0 | 96 |
| PUBLICATION DEVELOPMENT SUPPORT IN RELATION TO HYSTERECTOMY AND THE AVAILABLE DATA ON THE POTENTIAL LONG-TERM COMPLICATIONS OF ITS USE | $4,615 | 2 | 2 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Gynecology | $81,609 | 3 | $27,203 |
| Reproductive Endocrinology | $33,140 | 12 | $2,762 |
| Urology | $4,186 | 14 | $299.00 |
| Gastroenterology | $3,589 | 1 | $3,589 |
| Obstetrics & Gynecology | $3,049 | 16 | $190.56 |
| Specialist | $1,656 | 2 | $827.79 |
| Student in an Organized Health Care Education/Training Program | $246.80 | 4 | $61.70 |
| Radiation Oncology | $206.28 | 9 | $22.92 |
| Nurse Practitioner | $147.92 | 2 | $73.96 |
| Pediatric Urology | $125.00 | 1 | $125.00 |
| Surgical | $125.00 | 1 | $125.00 |
| Surgical Oncology | $22.92 | 1 | $22.92 |
| Therapeutic Radiology | $22.92 | 1 | $22.92 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. Kelly Roy, Md, MD | Gynecology | Phoenix, AZ | $75,501 | $0 |
| Dr. James Simon, M.d, M.D | Reproductive Endocrinology | Washington, DC | $32,597 | $0 |
| Andrea Lukes, M.d, M.D | Gynecology | Durham, NC | $3,801 | $0 |
| Dr. Paul Watkins, Md, MD | Gastroenterology | Chapel Hill, NC | $3,589 | $0 |
| Dr. Jose De La Cerda, M.d, M.D | Urology | San Antonio, TX | $2,711 | $0 |
| Ayman Al-Hendy | Obstetrics & Gynecology | Chicago, IL | $2,307 | $0 |
| Obianuju Madueke-Laveaux, M.d, M.D | Gynecology | Chicago, IL | $2,307 | $0 |
| Jeffrey Frankel, Md, MD | Specialist | Burien, WA | $1,531 | $0 |
| Brian Hu, Md, MD | Urology | Loma Linda, CA | $125.00 | $0 |
| Dr. Albert Mcbride, Md, MD | Urology | Bakersfield, CA | $125.00 | $0 |
| Dr. Jeffrey Herz, M.d, M.D | Urology | Rancho Mirage, CA | $125.00 | $0 |
| Dr. William Bodenstab, M.d, M.D | Urology | Lihue, HI | $125.00 | $0 |
| Jeffrey Evans, Md, MD | Urology | Seattle, WA | $125.00 | $0 |
| John Edwards, Md, MD | Urology | Pasadena, CA | $125.00 | $0 |
| Dr. Sean Okeefe, Md, MD | Urology | Bellingham, WA | $125.00 | $0 |
| Mr. Mark Fritzler, Md, MD | Urology | Chico, CA | $125.00 | $0 |
| Dr. Michael Scott, M.d, M.D | Pediatric Urology | Lynwood, CA | $125.00 | $0 |
| Dr. Madhu Alagiri, M.d, M.D | Urology | San Diego, CA | $125.00 | $0 |
| Fredrick Wolk, M.d, M.D | Specialist | Redondo Beach, CA | $125.00 | $0 |
| Suzanne Lange, Md, MD | Urology | Colorado Springs, CO | $125.00 | $0 |
| Jennifer Botelho, Pa-C, PA-C | Surgical | Portland, OR | $125.00 | $0 |
| Dr. Gregory Hosier, Md, Msc, MD, MSC | Urology | San Francisco, CA | $125.00 | $0 |
| Klinton Brearton, Dnp, DNP | Nurse Practitioner | Orem, UT | $125.00 | $0 |
| William Tu, M.d, M.D | Student in an Organized Health Care Education/Training Program | Stanford, CA | $125.00 | $0 |
| Andrew Rockwood, M.d, M.D | Urology | Fredericksburg, TX | $50.00 | $0 |
Ad
Top Products
- ORGOVYX $3.4M
- MYFEMBREE $3.2M
Payment Categories
- Food & Beverage $4,019
- Consulting $3,589
- Travel & Lodging $5,444
- Research $6.7M
About Myovant Sciences GmbH
Myovant Sciences GmbH has made $6.7M in payments to 68 healthcare providers, recorded across 1,240 transactions in the CMS Open Payments database. In 2022, the company paid $3.8M. The top product by payment volume is ORGOVYX ($3.4M).
Payments were distributed across 13 medical specialties. The top specialty by payment amount is Gynecology ($81,609 to 3 doctors).
Payment categories include: Food & Beverage ($4,019), Consulting ($3,589), Research ($6.7M), Travel & Lodging ($5,444).